Literature DB >> 16105496

Atrial fibrillation: how to approach rate control.

Lynda E Rosenfeld1.   

Abstract

The optimal management of atrial fibrillation is of considerable clinical importance, and with the recent publication of four studies suggesting the equivalence of rate and rhythm control strategies, new attention has been focused on rate control. Reasons for rate control include reduction of symptoms and the prevention of tachycardia-mediated cardiomyopathy; yet, evidence-based definitions of optimal rate control are lacking. This article examines an approach to rate control that includes serial assessment of heart rate and symptoms, both at rest and with exertion, and the use of therapy tailored to the individual and modified over time (as no single therapy demonstrates clear superiority). Often, multidrug regimens including digoxin and a calcium channel blocker or beta-blocker are required, and in a minority of patients atrioventricular nodal ablation and pacing are necessary. Several novel therapies currently under development are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105496     DOI: 10.1007/s11886-005-0094-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  50 in total

1.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

Review 2.  Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology.

Authors:  S Lévy; G Breithardt; R W Campbell; A J Camm; J C Daubert; M Allessie; E Aliot; A Capucci; F Cosio; H Crijns; L Jordaens; R N Hauer; F Lombardi; B Lüderitz
Journal:  Eur Heart J       Date:  1998-09       Impact factor: 29.983

3.  Diltiazem and exercise performance in patients with chronic atrial fibrillation.

Authors:  J E Atwood; J N Myers; M J Sullivan; S M Forbes; W F Pewen; V F Froelicher
Journal:  Chest       Date:  1988-01       Impact factor: 9.410

4.  What is meant by a "controlled" ventricular rate in atrial fibrillation?

Authors:  J M Rawles
Journal:  Br Heart J       Date:  1990-03

5.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

6.  The beneficial effects of verapamil in chronic atrial fibrillation.

Authors:  H O Klein; H Pauzner; E Di Segni; D David; E Kaplinsky
Journal:  Arch Intern Med       Date:  1979-07

7.  Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation.

Authors:  Shaowei Zhuang; Youhua Zhang; Kent A Mowrey; Jianbo Li; Tomotsugu Tabata; Don W Wallick; Zoran B Popović; Richard A Grimm; Andrea Natale; Todor N Mazgalev
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

8.  Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent.

Authors:  D David; E D Segni; H O Klein; E Kaplinsky
Journal:  Am J Cardiol       Date:  1979-12       Impact factor: 2.778

9.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.

Authors:  D L Packer; G H Bardy; S J Worley; M S Smith; F R Cobb; R E Coleman; J J Gallagher; L D German
Journal:  Am J Cardiol       Date:  1986-03-01       Impact factor: 2.778

10.  Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1993-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.